My reply (sarcastic) to the bunny: I'm sure the
Post# of 72440
Quote:
I'm sure the stock will still be $1 if P is shown to be superior to Otezla in P2b. The same for positive data of B-UP and B-OM.
BP: Who needs an oral psoriasis drug that's superior to a $1B drug anyway?
CTIX: Just one P3 trial with few patients?
BP: Not interested.
CTIX: How about five more years of market exclusivity?
BP: Still not interested.
CTIX: Why did you sign the CDA then?
BP: Hmmm...